Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will UN Report On Access To Medicines Change Anything?

Executive Summary

Industry opposes interference with intellectual property rights but is open to compulsory licensing and delinking R&D cost to drug prices in limited situations.

Advertisement

Related Content

UN Panel Report: Positions Still Polarized Over Medicines Access Barriers
More Pressure On Pharma: UN Report Backs Compulsory Licensing
GSK Is First To Share Cancer Drug Patents With Poor Countries

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel